Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Blue Trust Inc.

Blue Trust Inc. lifted its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 344.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,697 shares of the biotechnology company’s stock after acquiring an additional 6,740 shares during the quarter. Blue Trust Inc.’s holdings in Grifols were worth $65,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. R Squared Ltd bought a new position in Grifols during the 4th quarter valued at $28,000. GAMMA Investing LLC raised its stake in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 2,153 shares during the period. HighTower Advisors LLC boosted its stake in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,546 shares in the last quarter. Finally, Tidal Investments LLC acquired a new position in Grifols during the third quarter worth about $147,000.

Grifols Stock Down 0.3 %

Shares of Grifols stock opened at $7.43 on Tuesday. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $9.96. The firm has a market capitalization of $5.11 billion, a PE ratio of 6.35 and a beta of 0.40. The stock’s fifty day moving average is $7.37 and its 200-day moving average is $8.09.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GRFS. Morgan Stanley began coverage on shares of Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating for the company. Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.